Breaking News, Collaborations & Alliances

Caris Life Sciences and Ontada Partner to Advance Oncology Research

Aim to accelerate the development of next-generation oncology therapies by leveraging a combined dataset.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

Caris Life Sciences, a provider of molecular profiling and artificial intelligence (AI)-driven solutions for cancer treatment, today announced a strategic collaboration with Ontada, a provider of oncology real-world evidence (RWE) and clinical education solutions.

The partnership aims to accelerate the development of next-generation oncology therapies by leveraging a combined dataset encompassing millions of patient records and over 13 quadrillion data points. This data will be used to conduct research, develop new data solutions, and inform clinical decision-making.

“Rooted in a commitment to rigorous science and cancer care, the collaboration between Caris and Ontada includes strategic pillars spanning the development and delivery of multimodal data solutions, innovative research strategies and data-driven practices to provide actionable cancer care intelligence,” said Caris President David Spetzler, MS, PhD, MBA. “By seamlessly integrating key entities of research, biopharma and patients, we collectively aim to revolutionize cancer research, drive innovation, advance precision medicine and improve patient outcomes.”

“By bringing together two of the most extensive clinical and genomic data sets in community oncology, we have developed a unique resource for life sciences companies. Our goal with this resource is to empower them to address complex questions, potentially leading to groundbreaking research and improved cancer care,” said Christine Davis, Ontada President. “Given the rapid evolution of oncology, this collaboration enables us to deliver insights more quickly, conduct more robust research and continue advancing precision care.”

Caris and Ontada will work together to connect research with real-world applications. They aim to create a seamless transition from research and development to clinical practice, enabling patients to access more informed treatment choices, personalized therapies, clinical trials, and better outcomes more quickly.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics